Start-Ups Set Sights on Flu
This article was originally published in Start Up
Executive Summary
The swine flu/H1N1 pandemic presents a lucrative opportunity for drug developers and Big Pharmas won't be the only firms to capitalize on the sudden multibillion-dollar opportunity. There's evidence that the pandemic is driving investors to flu-focused biotechs as well. In this issue, we profile four emerging companies that hope to reap the rewards of what should continue to be a promising fund-raising environment for potentially novel flu therapies.
You may also be interested in...
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2009
Highlights from the Q2 2009 review of pharmaceutical and biotechnology dealmaking: In biopharma financing, the FOPO had a comeback bringing in $773 million with 11 transactions--a deal volume the public markets haven't achieved since Q1 2008. Cephalon and Dendreon led the pack, each with follow-on offerings exceeding the $100 million mark. There weren't the mega Big Pharma mergers done in previous months, however, there was a clear interest in generics as witnessed by Sanofi-Aventis' buyouts of two generics firms, and Watson and Novartis also getting in on the action, each through $1 billion+ acquisitions in this arena as well. As far as alliances were concerned, the top spot belongs to GlobeImmune, which granted Celgene exclusive worldwide rights to its {Targomen} cancer programs (including two clinical-stage candidates) in exchange for a potential $540 million pay day.Q2 also saw many companies shifting therapeutic focus to in-license products and candidates new to them in order to revive pipelines and beef up portfolios.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2009
Highlights from the Q2 2009 review of pharmaceutical and biotechnology dealmaking: In biopharma financing, the FOPO had a comeback bringing in $773 million with 11 transactions--a deal volume the public markets haven't achieved since Q1 2008. Cephalon and Dendreon led the pack, each with follow-on offerings exceeding the $100 million mark. There weren't the mega Big Pharma mergers done in previous months, however, there was a clear interest in generics as witnessed by Sanofi-Aventis' buyouts of two generics firms, and Watson and Novartis also getting in on the action, each through $1 billion+ acquisitions in this arena as well. As far as alliances were concerned, the top spot belongs to GlobeImmune, which granted Celgene exclusive worldwide rights to its {Targomen} cancer programs (including two clinical-stage candidates) in exchange for a potential $540 million pay day.Q2 also saw many companies shifting therapeutic focus to in-license products and candidates new to them in order to revive pipelines and beef up portfolios.
As WHO Declares Swine Flu Pandemic, Vaccine Makers Could Soon Be Wallowing In Profits
HONG KONG - Demand is likely to increase for an A/H1N1 vaccine following a decision by the World Health Organization to declare a pandemic, even if the alert upgrade is unlikely to do much to speed up production already underway